Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3090 Retrospective Experience with Pherochromocytoma (PH) and Paraganglioma (PG) in a Single Argentinian Institution

Introduction: Pherochromocytoma (PH) and paraganglioma (PG) are neuroendocrine tumors arising in cromaffin cells in the adrenal medulla or extra adrenal paraganglia respectively. Clinical presentation is diverse. All PG/PH have malignant potential. Hereditary cases comprise up to 40% of all PG/PH.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dioca M, Calabretta M, Iglesias L, Rojas Bilbao E, Califano I,

Keywords: Pherochromocytoma and paraganglioma (PG),

#3082 MEN1 Associated pNETs: A Case Series from Two Centres of Excellence in the United Kingdom

Introduction: Literature on MEN1 associated PNETS as a unique clinico-pathological entity is evolving.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Venkataraman H

Authors: Venkataraman H, Hegde P, Purewal T, Smith S, Vicarage S,

Keywords: Pancreatic neuroendocrine tumors, Multiple endocrine neoplasia, sporadic pancreatic neuroendocrine tumors,

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#3078 Gastroenteropancreatic Neuroendocrine Tumor: Experience of an Algerian Centre

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs) constitute a rare and heterogeneous group of tumors and still constitute a diagnostic and therapeutic challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Aris H, Ghomari S,

Keywords: gastroenteropancreatic neuroendocrine tumor, centre experience, treatment, survival,

#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study

Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,